Hemophilia Treatment Drugs Market

Hemophilia Treatment Drugs Market (Product Type - Recombinant Coagulation Factor Concentrates, Plasma derived Coagulation Factor Concentrates; Disease Indication - Hemophilia A, Hemophilia B, Others; Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026

Hemophilia Treatment Drugs Market - Snapshot

The global hemophilia treatment drugs market was valued at US$ 9,500 Mn in 2017 and is anticipated to reach US$ 15,000 Mn by 2026, expanding at a CAGR of 5% from 2018 to 2026. Increase in R&D investment by key players for developing new drugs for the treatment of hemophilia and rise in demand for long-acting replacement therapies and non-factor therapies are anticipated to fuel the growth of the global market during the forecast period. North America dominated the global market in 2017 owing to the introduction and uptake of new long-acting factors and alternative coagulation promoters and increase in the rate of diagnosis for hemophilia.

hemophilia treatment industry

The global hemophilia treatment drugs market is driven by government initiatives such as nationwide network of hemophilia treatment centers (HTCs) funded by the Federal Government in the U.S. Many of the HTCs are located at major university medical and research centers. The Federal Government in the U.S. provides funds for more than 100 HTCs. Treatment, education, and support are provided by medical experts at these HTCs. Patients who are provided care and treated at HTCs are less likely to have hospitalization and bleeding complications than those who avail care elsewhere.

The global hemophilia treatment drugs market has been segmented based on product type, disease indication, distribution channel, and region. In terms of product type, the recombinant coagulation factor concentrates segment is projected to account for significant share of the market during the forecast period. New recombinant pipeline agents and gene therapies, such as Fitusiran (phase III trials) and valoctocogene roxaparvovec (phase III candidate), are expected to gain market share during the forecast period. However, some products such as CSL-689 (phase II/III for hemophilia A and hemophilia B) are likely to account for small market share, as these are positioned as on-demand treatments in a market that is increasingly moving toward prophylaxis.

In terms of disease, the global hemophilia treatment drugs market has been classified into hemophilia A, hemophilia B, and others. The hemophilia A segment accounted for major share of the global hemophilia treatment drugs market in 2017. According to the Centers for Disease Control and Prevention (CDC), the exact number of people living with hemophilia globally is not known; however, hemophilia A affects 1 in 5,000 male births. About 400 babies are born with hemophilia A each year. In terms of distribution channel, the global hemophilia treatment drugs market has been categorized into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment held major market share in 2017. The segment is likely to account for leading share of the market during the forecast period.

In terms of region, the global hemophilia treatment drugs market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America and Europe accounted for major shares of the global hemophilia treatment drugs market in 2017 and the trend is likely to continue from 2018 to 2026. High rate of immigration from tropical regions, increase in health care budgets by governments, and government initiatives to promote hemophilia treatment contributed to the leading shares of these regions. Asia Pacific is projected to be the most attractive market for hemophilia treatment drugs during the forecast period. The market in Asia Pacific is expected to expand at a high CAGR from 2018 to 2026 due to large number of hemophilia patients opting for recombinant coagulation factor concentrates in developing countries such as India and China. The market in Latin America is poised to expand at a moderate growth rate during the forecast period.

Prominent players operating in the global hemophilia treatment drugs market include Pfizer, Inc., CSL Behring, Kedrion, Shire plc, Novo Nordisk A/S, Bayer AG, F. Hoffmann-La Roche Ltd., and Sanofi. Shire plc accounted for the largest market share in 2017. The company’s dominance of the market is due to its broad product portfolio, extensive geographical presence, and aggressive acquisition strategies. Shire plc strengthened its market position by acquiring Baxalta in June 2016. Baxalta is a key player in the rare diseases and other specialized disorders segments.

Novo Nordisk A/S accounted for the second largest share of the global hemophilia treatment drugs market in 2017 due to wide range of hemophilia drugs and robust pipeline. However, F. Hoffmann-La Roche, a new entrant in the hemophilia treatment drugs market, is expected to outperform Novo Nordisk during the forecast period. Pfizer held the third largest share of the hemophilia treatment drugs market in 2017.

Rising Danger of Hemophilia Cases will Bring Profitable Growth for the Hemophilia Treatment Drugs Market

The hemophilia treatment drugs market is expected to gain tremendous growth opportunities on the back of the rising cases of hemophilia across the globe. The growing number of cases related to hemophilia around the world will serve as a prominent growth factor during the assessment period of 2018-2026.

  • Hemophilia is a bleeding disorder. In this condition, a person’s blood does not clot properly which leads to many problems such as spontaneous bleeding and others. This disease is most prevalent among men. Drugs approved for the treatment of hemophilia are known as hemophilia treatment drugs.
  • According to the Centers for Disease Control and Prevention (CDC), about 400 babies are born with hemophilia A in the U.S. Nearly 33000 males are living with the disorder in the U.S. as per the survey by the CDC. The rising number of patients with hemophilia is directly proportional to the growth of the hemophilia treatment drugs market.
  • Research and development activities have a vital role in the growth of the hemophilia treatment drugs market. The players in the hemophilia treatment drugs market invest heavily in these activities for developing new formulations that are beneficial for the patients and treat hemophilia more easily and rapidly. Such formulations help in boosting the revenues of the players in the hemophilia treatment drugs market, eventually increasing the growth rate.
  • Strategic collaborations also play a major role in the growth of the hemophilia treatment drugs market. The players in the hemophilia treatment drugs market indulge in these activities for strengthening their foothold, ultimately increasing the growth prospects across the hemophilia treatment drugs market.
  • Quick approvals for drugs from regulatory authorities are proving to be game-changers for the hemophilia treatment drugs market. The increasing efforts of the government bodies of numerous countries to provide advanced therapies for hemophilia may also bring immense growth opportunities.

The global hemophilia treatment drugs market has been segmented as follows:

Product

  • Recombinant coagulation factor concentrates
    • Factor VIII
    • Factor IX
    • Others
  • Plasma-derived coagulation factor concentrates
    • Factor VIII
    • Factor IX
    • Others
  • Others

Disease Indication

  • Hemophilia A
  • Hemophilia B
  • Others

Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Region

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • India
    • China
    • Japan
    • Australia & New Zealand
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • South Africa
    • GCC countries
    • Rest of MEA

     

    1. Preface
         1.1. Market Definition and Scope
         1.2. Market Segmentation
         1.3. Key Research Objectives
         1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary : Global Hemophilia Treatment Drugs Market

    4. Market Overview
         4.1. Introduction
                4.1.1. Product Type Definition
                4.1.2. Industry Evolution / Developments
         4.2. Overview
         4.3. Market Dynamics
                4.3.1. Drivers
                4.3.2. Restraints
                4.3.3. Opportunities
         4.4. Global Hemophilia Treatment Drugs Market Analysis and Forecast, 2016–2026
                4.4.1. Market Revenue Projections (US$ Mn)
         4.5. Porter’s Five Force Analysis

    5. Market Outlook
         5.1. Regulatory Scenario by Region/globally
         5.2. Key Mergers & Acquisitions 
         5.3. Pipeline Analysis
         5.4. Clinical Trial Analysis
         5.5. Technological Advancements

    6. Global Hemophilia Treatment Drugs Market Analysis and Forecast, by Product Type 
         6.1. Introduction & Definition
         6.2. Key Findings / Developments
         6.3. Global Hemophilia Treatment Drugs Market Value Forecast, by Product Type, 2016–2026
                6.3.1. Plasma derived coagulation factor concentrates 
                         6.3.1.1. Factor VIII
                         6.3.1.2. Factor IX
                         6.3.1.3. Others
                6.3.2. Recombinant coagulation factor concentrates 
                         6.3.2.1. Factor VIII
                         6.3.2.2. Factor IX
                         6.3.2.3. Others
                6.3.3. Others
         6.4. Global Hemophilia Treatment Drugs Market Attractiveness, by Product Type

    7. Global Hemophilia Treatment Drugs Market Analysis and Forecast, by Disease Indication 
         7.1. Introduction & Definition
         7.2. Key Findings / Developments
         7.3. Global Hemophilia Treatment Drugs Market Value Forecast by Disease Indication, 2016–2026
                7.3.1. Hemophilia A
                7.3.2. Hemophilia B
                7.3.3. Others
         7.4. Global Hemophilia Treatment Drugs Market Attractiveness, by Disease Indication

    8. Global Hemophilia Treatment Drugs Market Analysis and Forecast, by Distribution Channel 
         8.1. Introduction & Definition
         8.2. Key Findings / Developments
         8.3. Global Hemophilia Treatment Drugs Market Value Forecast, by Distribution Channel, 2016–2026
                8.3.1. Hospital Pharmacies 
                8.3.2. Retail Pharmacies 
                8.3.3. Online Pharmacies
         8.4. Global Hemophilia Treatment Drugs Market Attractiveness, by Distribution Channel

    9. Global Hemophilia Treatment Drugs Market Analysis and Forecast, by Region
         9.1. Key Findings
         9.2. Global Hemophilia Treatment Drugs Market Value Forecast, by Region
                9.2.1. North America 
                9.2.2. Europe 
                9.2.3. Asia Pacific 
                9.2.4. Latin America 
                9.2.5. Middle East & Africa 
         9.3. Global Hemophilia Treatment Drugs Market Attractiveness, by Country/Region

    10. North America Hemophilia Treatment Drugs Market Analysis and Forecast
         10.1. Introduction
                10.1.1. Key Findings
         10.2. North America Hemophilia Treatment Drugs Market Value Forecast, by Product Type, 2016–2026
                10.2.1. Plasma derived coagulation factor concentrates 
                         10.2.1.1. Factor VIII
                         10.2.1.2. Factor IX
                         10.2.1.3. Others
                10.2.2. Recombinant coagulation factor concentrates 
                         10.2.2.1. Factor VIII
                         10.2.2.2. Factor IX
                         10.2.2.3. Others
                10.2.3. Others
         10.3. North America Hemophilia Treatment Drugs Market Value Forecast, by Disease Indication, 2016–2026
                10.3.1. Hemophilia A
                10.3.2. Hemophilia B
                10.3.3. Others
         10.4. North America Hemophilia Treatment Drugs Market Value Forecast, by Distribution Channel, 2016–2026
                10.4.1. Hospital Pharmacies 
                10.4.2. Retail Pharmacies 
                10.4.3. Online Pharmacies
         10.5. North America Hemophilia Treatment Drugs Market Value Forecast by Country, 2016–2026
                10.5.1. U.S.
                10.5.2. Canada
         10.6. North America Hemophilia Treatment Drugs Market Attractiveness Analysis 
                       10.6.1. By Product Type 
                10.6.2. By Disease Indication 
                10.6.3. By Distribution Channel 
                10.6.4. By Country

    11. Europe Hemophilia Treatment Drugs Market Analysis and Forecast
         11.1.Introduction
         11.1.1. Key Findings
         11.2. Europe Hemophilia Treatment Drugs Market Value Forecast, by Product Type, 2016–2026
                11.2.1. Plasma derived coagulation factor concentrates 
                         11.2.1.1. Factor VIII
                         11.2.1.2. Factor IX
                         11.2.1.3. Others
                11.2.2. Recombinant coagulation factor concentrates 
                         11.2.2.1. Factor VIII
                         11.2.2.2. Factor IX
                         11.2.2.3. Others
                11.2.3. Others
         11.3. Europe Hemophilia Treatment Drugs Market Value Forecast, by Disease Indication, 2016–2026
                11.3.1. Hemophilia A
                11.3.2. Hemophilia B
                11.3.3. Others
         11.4. Europe Hemophilia Treatment Drugs Market Value Forecast, by Distribution Channel, 2016–2026
                11.4.1. Hospital Pharmacies 
                11.4.2. Retail Pharmacies 
                11.4.3. Online Pharmacies
         11.5. Europe Hemophilia Treatment Drugs Market Value Forecast, by Country/Sub-region, 2016–2026
                11.5.1. Germany
                11.5.2. U.K.
                11.5.3. France
                11.5.4. Spain
                11.5.5. Italy
                11.5.6. Rest of Europe
         11.6. Europe Hemophilia Treatment Drugs Market Attractiveness Analysis 
                11.6.1. By Product Type 
                11.6.2. By Disease Indication 
                11.6.3. By Distribution Channel 
                11.6.4. By Country/Sub-region

    12. Asia Pacific Hemophilia Treatment Drugs Market Analysis and Forecast
         12.1.Introduction
                12.1.1. Key Findings
         12.2. Asia Pacific Hemophilia Treatment Drugs Market Value Forecast, by Product Type, 2016–2026
                12.2.1. Plasma derived coagulation factor concentrates 
                        12.2.1.1. Factor VIII
                         12.2.1.2. Factor IX
                         12.2.1.3. Others
                12.2.2. Recombinant coagulation factor concentrates 
                         12.2.2.1. Factor VIII
                         12.2.2.2. Factor IX
                         12.2.2.3. Others
                12.2.3. Others
         12.3. Asia Pacific Hemophilia Treatment Drugs Market Value Forecast, by Disease Indication, 2016–2026
                12.3.1. Hemophilia A
                12.3.2. Hemophilia B
                12.3.3. Others
         12.4. Asia Pacific Hemophilia Treatment Drugs Market Value Forecast, by Distribution Channel, 2016–2026
                12.4.1. Hospital Pharmacies 
                12.4.2. Retail Pharmacies 
                12.4.3. Online Pharmacies
         12.5. Asia Pacific Hemophilia Treatment Drugs Market Value Forecast, by Country/Sub-region, 2016–2026
                12.5.1. China
                12.5.2. Japan
                12.5.3. India
                12.5.4. Australia & New Zealand
                12.5.5. Rest of Asia Pacific
         12.6. Asia Pacific Hemophilia Treatment Drugs Market Attractiveness Analysis 
                12.6.1. By Product Type 
                12.6.2. By Disease Indication 
                12.6.3. By Distribution Channel 
                12.6.4. By Country/Sub-region

    13. Latin America Hemophilia Treatment Drugs Market Analysis and Forecast
         13.1.Introduction
                13.1.1. Key Findings
         13.2. Latin America Hemophilia Treatment Drugs Market Value Forecast by Product Type, 2016–2026
                13.2.1. Plasma derived coagulation factor concentrates 
                         13.2.1.1. Factor VIII
                         13.2.1.2. Factor IX
                         13.2.1.3. Others
                13.2.2. Recombinant coagulation factor concentrates 
                         13.2.2.1. Factor VIII
                         13.2.2.2. Factor IX
                         13.2.2.3. Others
         13.3. Latin America Hemophilia Treatment Drugs Market Value Forecast, by Disease Indication, 2016–2026
                13.3.1. Hemophilia A
                13.3.2. Hemophilia B
                13.3.3. Others
         13.4. Latin America Hemophilia Treatment Drugs Market Value Forecast, by Distribution Channel, 2016–2026
                13.4.1. Hospital Pharmacies 
                13.4.2. Retail Pharmacies 
                13.4.3. Online Pharmacies
         13.5. Latin America Hemophilia Treatment Drugs Market Value Forecast, by Country/Sub-region, 2016–2026
                13.5.1. Brazil
                13.5.2. Mexico
                13.5.3. Rest of Latin America
         13.6. Latin America Hemophilia Treatment Drugs Market Attractiveness Analysis 
                13.6.1. By Product Type 
                13.6.2. By Disease Indication 
                13.6.3. By Distribution Channel 
                13.6.4. By Country

    14. Middle East & Africa Hemophilia Treatment Drugs Market Analysis and Forecast
         14.1.Introduction
                14.1.1. Key Findings
         14.2. Middle East & Africa Hemophilia Treatment Drugs Market Value Forecast, by Product Type, 2016–2026
                14.2.1. Plasma derived coagulation factor concentrates 
                         14.2.1.1. Factor VIII
                         14.2.1.2. Factor IX
                         14.2.1.3. Others
                14.2.2. Recombinant coagulation factor concentrates 
                         14.2.2.1. Factor VIII
                         14.2.2.2. Factor IX
                         14.2.2.3. Others
                14.2.3. Others
         14.3. Middle East & Africa Hemophilia Treatment Drugs Market Value Forecast, by Disease Indication, 2016–2026
                14.3.1. Hemophilia A
                14.3.2. Hemophilia B
                14.3.3. Others
         14.4. Middle East & Africa Hemophilia Treatment Drugs Market Value Forecast, by Distribution Channel, 2016–2026
                14.4.1. Hospital Pharmacies 
                14.4.2. Retail Pharmacies 
                14.4.3. Online Pharmacies
         14.5. Middle East & Africa Hemophilia Treatment Drugs Market Value Forecast, by Country/Sub-region, 2016–2026
                14.5.1. GCC Countries
                14.5.2. South Africa
                14.5.3. Rest of Middle East & Africa
         14.6. Middle East & Africa Hemophilia Treatment Drugs Market Attractiveness Analysis 
                14.6.1. By Product Type 
                14.6.2. By Disease Indication 
                14.6.3. By Distribution Channel 
                14.6.4. By Country/Sub-region

    15. Competition Landscape
         15.1.Market Player – Competition Matrix (by Tier and Size of companies)
         15.2.Market Share Analysis by Company (2017)
         15.3. Company Profiles
                15.3.1. Biotest AG.
                         15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
                         15.3.1.2. Business Overview
                         15.3.1.3. Product Portfolio 
                         15.3.1.4. Financial Overview 
                         15.3.1.5. SWOT Analysis 
                         15.3.1.6. Strategic overview
                15.3.2. Bayer AG
                         15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
                         15.3.2.2. Business Overview
                         15.3.2.3. Product Portfolio 
                         15.3.2.4. Financial Overview 
                         15.3.2.5. SWOT Analysis 
                15.3.3. CSL Limited
                         15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
                         15.3.3.2. Business Overview
                         15.3.3.3. Product Portfolio 
                         15.3.3.4. Financial Overview 
                         15.3.3.5. SWOT Analysis 
                         15.3.3.6. Strategic overview
                15.3.4. F. Hoffmann-La Roche Ltd.
                         15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
                         15.3.4.2. Business Overview
                         15.3.4.3. Product Portfolio 
                         15.3.4.4. Financial Overview 
                         15.3.4.5. SWOT Analysis 
                         15.3.4.6. Strategic overview 
                15.3.5. Kedrion
                         15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
                         15.3.5.2. Business Overview
                         15.3.5.3. Product Portfolio 
                         15.3.5.4. Financial Overview 
                         15.3.5.5. SWOT Analysis 
                         15.3.5.6. Strategic overview
                15.3.6. Novo Nordisk A/S
                                         15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
                         15.3.6.2. Business Overview
                         15.3.6.3. Product Portfolio 
                         15.3.6.4. Financial Overview 
                         15.3.6.5. SWOT Analysis 
                         15.3.6.6. Strategic overview
                15.3.7. Octapharma
                         15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
                         15.3.7.2. Business Overview
                         15.3.7.3. Product Portfolio 
                         15.3.7.4. Financial Overview 
                         15.3.7.5. SWOT Analysis 
                         15.3.7.6. Strategic overview
                15.3.8. Pfizer, Inc
                         15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
                         15.3.8.2. Business Overview
                         15.3.8.3. Product Portfolio 
                         15.3.8.4. Financial Overview 
                         15.3.8.5. SWOT Analysis 
                         15.3.8.6. Strategic overview 
                15.3.9. Sanofi
                         15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
                         15.3.9.2. Business Overview
                         15.3.9.3. Product Portfolio 
                         15.3.9.4. Financial Overview 
                         15.3.9.5. SWOT Analysis 
                         15.3.9.6. Strategic overview
               15.3.10. Shire Plc.
                         15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
                         15.3.10.2. Business Overview
                         15.3.10.3. Product Portfolio 
                         15.3.10.4. Financial Overview 
                         15.3.10.5. SWOT Analysis 
                         15.3.10.6. Strategic overview

    List of Tables

    Table 01 Global Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast, by Product Type, 2016–2026
    Table 02 Global Hemophilia Treatment Drugs Market Value (US$ Mn) Forecast, by Recombinant Coagulation Factor Concentrates, 2016–2026
    Table 03 Global Hemophilia Treatment Drugs Market Value (US$ Mn) Forecast, by Plasma derived coagulation factor concentrates, 2016–2026
    Table 04 Global Hemophilia Treatment Drugs Market Value (US$ Mn) Forecast, by Disease Indication, 2016–2026
    Table 05 Global Hemophilia Treatment Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
    Table 06 North America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast, by Country, 2016–2026
    Table 07 North America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast, by Product Type, 2016–2026
    Table 08 North America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast, by Disease Indication, 2016–2026
    Table 09 North America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
    Table 10 Europe Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
    Table 11 Europe Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast, by Product Type, 2016–2026
    Table 12 Europe Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast, by Disease Indication, 2016–2026
    Table 13 Europe Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
    Table 14 Asia Pacific Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
    Table 15 Asia Pacific Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast, by Product Type, 2016–2026
    Table 16 Asia Pacific Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast, by Disease Indication, 2016–2026
    Table 17 Asia Pacific Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
    Table 18 Latin America  Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
    Table 19 Latin America  Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast, by Product Type, 2016–2026
    Table 20 Latin America  Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast, by Disease Indication, 2016–2026
    Table 21 Latin America  Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
    Table 22 Middle East & Africa Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
    Table 23 Middle East & Africa Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast, by Product Type, 2016–2026
    Table 24 Middle East & Africa Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast, by Disease Indication, 2016–2026
    Table 25 Middle East & Africa Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026

     

    List of Figures

    Figure 01 Global Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others)Market Size, by Product Type  (US$ Mn), 2017
    Figure 02 Global Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others)Market Share Analysis by Region, 2017
    Figure 03 Global Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others)Market Opportunity Map, by Product Type
    Figure 04 Global Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others)Market Opportunity Map, by Disease Indication
    Figure 05 Global Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others)Market Opportunity Map, by Distribution Channel 
    Figure 06 Global Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value Share, by Product Type, 2017 and 2026
    Figure 07 Global Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Attractiveness, by Product Type, 2018–2026
    Figure 08 Global Hemophilia Treatment Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), by Recombinant coagulation factor concentrates, 2016–2026
    Figure 09 Global Hemophilia Treatment Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), by Plasma-derived coagulation factor concentrates, 2016–2026
    Figure 10 Global Hemophilia Treatment Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), by Others, 2016–2026
    Figure 11 Global Bispecific & Next Generation Recombinant Products Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2026
    Figure 12 Global Gene Therapy Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2026
    Figure 13 Global Hemophilia Treatment Drugs Market Value Share, by Distribution Channel, 2017 and 2026
    Figure 14 Global Hemophilia Treatment Drugs Market Value Share, by Disease Indication, 2017 and 2026
    Figure 15 Global Hemophilia Treatment Drugs Market Attractiveness, by Disease Indication, 2018–2026
    Figure 16 Global Hemophilia Treatment Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), by Hemophilia A, 2016–2026
    Figure 17 Global Hemophilia Treatment Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), by Hemophilia B, 2016–2026
    Figure 18 Global Hemophilia Treatment Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), by Others, 2016–2026
    Figure 19 Global Hemophilia Treatment Drugs Market Value Share, by Distribution Channel, 2017 and 2026
    Figure 20 Global Hemophilia Treatment Drugs Market Attractiveness, by Distribution Channel, 2018–2026
    Figure 21 Global Hemophilia Treatment Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), by Hospital Pharmacies, 2016–2026
    Figure 22 Global Hemophilia Treatment Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), by Retail Pharmacies, 2016–2026
    Figure 23 Global Hemophilia Treatment Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), by Online Pharmacies, 2016–2026
    Figure 24 North America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2026
    Figure 25 North America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value Share, by Country, 2017 and 2026
    Figure 26 North America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Attractiveness, by Country, 2018–2026
    Figure 27 North America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value Share, by Product Type, 2017 and 2026
    Figure 28 North America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Attractiveness, by Product Type, 2018–2026
    Figure 29 North America Bispecific & Next Generation Recombinant Factor Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2026
    Figure 30 North America Gene Therapy Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2026
    Figure 31 North America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value Share, by Disease Indication, 2017 and 2026
    Figure 32 North America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Attractiveness, by Disease Indications, 2018–2026
    Figure 33 North America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value Share, by Distribution Channel, 2017 and 2026
    Figure 34 North America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Attractiveness, by Distribution Channel, 2018–2026
    Figure 35 Europe Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2026
    Figure 36 Europe Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value Share, by Country/Sub-region, 2017 and 2026
    Figure 37 Europe Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Attractiveness, by Country/Sub-region, 2018–2026
    Figure 38 Europe Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value Share, by Product Type, 2017 and 2026
    Figure 39 Europe Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Attractiveness, by Product Type, 2018–2026
    Figure 40 Europe Bispecific & Next Generation Recombinant Factor Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2026
    Figure 41 Europe Gene Therapy Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2026
    Figure 42 Europe Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value Share, by Disease Indication, 2017 and 2026
    Figure 43 Europe Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Attractiveness, by Disease Indications, 2018–2026
    Figure 44 Europe Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value Share, by Distribution Channel, 2017 and 2026
    Figure 45 Europe Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Attractiveness, by Distribution Channel, 2018–2026
    Figure 46 Asia Pacific Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2026
    Figure 47 Asia Pacific Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value Share, by Country/Sub-region, 2017 and 2026
    Figure 48 Asia Pacific Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Attractiveness, by Country/Sub-region, 2018–2026
    Figure 49 Asia Pacific Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value Share, by Product Type, 2017 and 2026
    Figure 50 Asia Pacific Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Attractiveness, by Product Type, 2018–2026
    Figure 51 Asia Pacific Bispecific & Next Generation Recombinant Factor Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2026
    Figure 52 Asia Pacific Gene Therapy Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2026
    Figure 53 Asia Pacific Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value Share, by Disease Indication, 2017 and 2026
    Figure 54 Asia Pacific Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Attractiveness, by Disease Indications, 2018–2026
    Figure 55 Asia Pacific Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value Share, by Distribution Channel, 2017 and 2026
    Figure 56 Asia Pacific Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Attractiveness, by Distribution Channel, 2018–2026
    Figure 57 Latin America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2026
    Figure 58 Latin America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value Share, by Country/Sub-region, 2017 and 2026
    Figure 59 Latin America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Attractiveness, by Country/Sub-region, 2018–2026
    Figure 60 Latin America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value Share, by Product Type, 2017 and 2026
    Figure 61 Latin America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Attractiveness, by Product Type, 2018–2026
    Figure 62 Latin America Bispecific & Next Generation Recombinant Factor Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2026
    Figure 63 Latin America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value Share, by Disease Indication, 2017 and 2026
    Figure 64 Latin America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Attractiveness, by Disease Indications, 2018–2026
    Figure 65 Latin America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value Share, by Distribution Channel, 2017 and 2026
    Figure 66 Latin America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Attractiveness, by Distribution Channel, 2018–2026
    Figure 67 Middle East & Africa Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2026
    Figure 68 Middle East & Africa Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value Share, by Country/Sub-region, 2017 and 2026
    Figure 69 Middle East & Africa Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Attractiveness, by Country/Sub-region, 2018–2026
    Figure 70 Middle East & Africa Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value Share, by Product Type, 2017 and 2026
    Figure 71 Middle East & Africa Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Attractiveness, by Product Type, 2018–2026
    Figure 72 Middle East & Africa Bispecific & Next Generation Recombinant Factor Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2026
    Figure 73 Middle East & Africa Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value Share, by Disease Indication, 2017 and 2026
    Figure 74 Middle East & Africa Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Attractiveness, by Disease Indications, 2018–2026
    Figure 75 Middle East & Africa Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value Share, by Distribution Channel, 2017 and 2026
    Figure 76 Middle East & Africa Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Attractiveness, by Distribution Channel, 2018–2026

Copyright © Transparency Market Research, Inc. All Rights reserved

We value your privacy

We use cookies to enhance your browsing experience, serve personalized ads or content, and analyze our traffic.

By clicking "Accept All", you consent to our use of cookies. Privacy Policy